Vivos Therapeutics financials
$0.1505+12.23%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $17.4M | $15.0M | $13.8M | $16.0M | $16.9M | $13.1M |
| Gross profit | $10.5M | $9.0M | $8.3M | $10.0M | $12.6M | $10.4M |
| Gross margin | 60.4% | 60.0% | 59.9% | 62.5% | 74.6% | 79.7% |
| Operating income | -$19.9M | -$11.2M | -$17.3M | -$25.0M | -$20.4M | -$12.0M |
| Net income | -$21.2M | -$11.1M | -$13.6M | -$23.8M | -$20.3M | -$18.0M |
| Net margin | −121.4% | −74.1% | −98.4% | −148.8% | −120.2% | −137.7% |
| Diluted EPS | $-2.07 | $-2.22 | $-11.14 | $-25.90 | $-24.00 | $-35.00 |
| EBITDA | -$18.6M | -$10.6M | -$16.7M | -$24.4M | -$18.7M | -$8.0M |
| Operating cash flow | -$15.3M | -$12.7M | -$11.9M | -$19.6M | -$15.7M | -$5.7M |
| Free cash flow | -$17.6M | -$13.3M | -$12.8M | -$20.5M | -$18.1M | -$5.8M |
| Diluted shares | 10.3M | 5.0M | 1.2M | 0.9M | 0.8M | 0.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.0M | $6.3M | $1.6M | $3.5M | $24.0M | $18.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $9.0M | $0.00 | $0.00 | $0.00 | $1.3M | $1.3M |
| Total assets | $25.2M | $15.3M | $10.7M | $13.7M | $33.7M | $25.3M |
| Total liabilities | $26.7M | $7.3M | $10.3M | $8.9M | $8.2M | $8.4M |
| Shareholders' equity | -$1.6M | $8.0M | $411.0K | $4.8M | $25.5M | $16.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology